Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiomics Feature Activation Maps as a New Tool for Signature Interpretability.
Vuong D, Tanadini-Lang S, Wu Z, Marks R, Unkelbach J, Hillinger S, Eboulet EI, Thierstein S, Peters S, Pless M, Guckenberger M, Bogowicz M. Vuong D, et al. Among authors: pless m. Front Oncol. 2020 Dec 8;10:578895. doi: 10.3389/fonc.2020.578895. eCollection 2020. Front Oncol. 2020. PMID: 33364192 Free PMC article.
Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials.
Nie R, Chen F, Provencio M, Wang Y, van den Ende T, van Laarhoven HWM, Yuan S, Pless M, Hayoz S, Zhou Z, Li Y, Rothschild SI, Cai M. Nie R, et al. Among authors: pless m. Eur J Cancer. 2023 Jun;186:211-221. doi: 10.1016/j.ejca.2023.03.010. Epub 2023 Mar 17. Eur J Cancer. 2023. PMID: 37062625 Free article.
Acute Fatal Liver Toxicity under Erlotinib.
Schacher-Kaufmann S, Pless M. Schacher-Kaufmann S, et al. Among authors: pless m. Case Rep Oncol. 2010 Jun 8;3(2):182-188. doi: 10.1159/000315366. Case Rep Oncol. 2010. PMID: 20740194 Free PMC article.
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
Mark M, Froesch P, Eboulet EI, Addeo A, Pless M, Rothschild SI, Janthur WD, Burmeister H, Friedlaender A, Schneider M, Metaxas Y, Joerger M, Wannesson L, Schwitter M, Baudoux N, Weindler S, Biaggi-Rudolf C, Früh M; Swiss Group for Clinical Cancer Research (SAKK). Mark M, et al. Among authors: pless m. Cancer Immunol Immunother. 2021 May;70(5):1255-1262. doi: 10.1007/s00262-020-02757-8. Epub 2020 Nov 1. Cancer Immunol Immunother. 2021. PMID: 33130956 Free PMC article. Clinical Trial.
199 results